Recent Advances in the Treatment of Prostate Cancer
EP. 1: Overview of Improvements in Prostate Cancer Management
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine,Evan Y. Yu, MD, Fred Hutchinson Cancer Research Center Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.
EP. 2: Optimizing Use of PSMA PET Imaging and PSADT in Prostate Cancer
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine,Evan Y. Yu, MD, Fred Hutchinson Cancer Research Center Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.
EP. 3: Evolving Treatment Landscape of Nonmetastatic CRPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.
EP. 4: Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.
EP. 5: Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life Measures
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD,Evan Y. Yu, MD A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).
EP. 6: Monitoring Strategies in Nonmetastatic CRPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].
EP. 7: Overview of Treatment for Metastatic HSPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.
EP. 8: Role of Micronized Abiraterone in Metastatic HSPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.
EP. 9: Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
EP. 10: Interpreting Data From the ARASENS Trial in Metastatic HSPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
EP. 11: Overview of Therapy for mCRPC: PARP Inhibitors
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
EP. 12: DNA Alterations and Selection of PARP Inhibitors in mCRPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
EP. 13: Metastatic CRPC: Utility of Imaging as a Biomarker
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.
EP. 14: Selecting Among Novel Imaging Options in Metastatic CRPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.
EP. 15: Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.
EP. 16: Addressing Bone and Visceral Metastases in Metastatic CRPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.
EP. 17: Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
EP. 18: Prostate Cancer Management: Future Directions in Care
ByAlicia Morgans, MD, MPH,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
